冠状动脉无复流现象的研究进展
《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]
- 期数:
- 2016年第5期
- 页码:
- 608-610,623
- 栏目:
- 综述
- 出版日期:
- 2016-04-25
文章信息/Info
- Title:
- Research progress of coronary no-reflow phenomenon
- Author(s):
- SUN Lei; SUN Dong-dong; WANG Hai-chang
- (Department of Cardiology, Xijing Hospital, Fourth Military University, Xi’an 710032, Shaanxi, China)
- Keywords:
- no-reflow; acute myocardial infarction; reperfusion
- 分类号:
- R542.2
- DOI:
- -
- 文献标识码:
- A
- 摘要:
- 再灌注治疗是急性心肌梗死（AMI）最重要的治疗方法之一，然而有部分患者在心外膜梗阻解除的情况下，心肌组织仍然呈低灌注状态，这一现象被称为“无复流”。无复流的确切机制至今尚不清楚，大量研究表明有多种可能的机制导致无复流的发生，主要机制有内皮细胞损伤、中性粒细胞聚集及氧自由基释放。发生无复流的患者预后常常较差，目前尚无治疗无复流的标准方法，主要治疗方法有药物治疗、血栓抽吸、远端保护装置及缺血预处理。本文将对介绍无复流的研究进展进行综述。
- Abstract:
- Reperfusion therapy is one of the most important treatments for acute myocardial infarction (AMI). In some case, obstruction of vascular epicardium is relieved, whereas myocardial tissue hypoperfusion remains. This phenomenon is called “no-reflow” whose exact mechanism is still unclear. Many studies have shown that there are several possible mechanisms leading to the occurrence of no-reflow, among which are endothelial cell injury, neutrophil accumulation and release of oxygen free radicals. Prognosis of patients with no-reflow is often poor and there is no standard treatment for no-reflow. Drug therapy, thrombectomy, distal protection devices and ischemic preconditioning are the major therapeutic approaches. This review mainly describes the research progress of the no-reflow phenomenon.
参考文献/References
[1]Chappell D,Hofmann-Kiefer K,Jacob M,et al.TNFalpha induced shedding of the endothelial glycocalyx is prevented by hydrocortisone and antithrombin[J].Basic Res Cardiol,2009,104(1):78-89.
[2]Kleinbongard P,Bose D,Baars T,et al.Vasoconstrictor potential of coronary aspirate from patients undergoing stenting of saphenous vein aortocoronary bypass grafts and its pharmacological attenuation[J].Circ Res,2011,108(3):344-352.
[3]Grygier M,Araszkiewicz A,Lesiak M,et al.New method of intracoronary adenosine injection to prevent microvascular reperfusion injury in patients with acute myocardial infarction undergoing percutaneous coronary intervention[J].Am J Cardiol,2011,107(8):1131-1135.
[4]Ndrepepa G,Tiroch K,Fusaro M,et al.5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction[J].J Am Coll Cardiol,2010,55(21):2383-2389.
[5]Oduncu V,Tanalp AC,Erkol A,et al.Impact of chronic pre-treatment of statins on the level of systemic inflammation and myocardial perfusion in patients undergoing primary angioplasty[J].Am J Cardiol,2011,107(2):179-185.
[6]Ndrepepa G,Tiroch K,Fusaro M,et al.5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction[J].J Am Coll Cardiol,2010,55(21):2383-2389.
[7]McGeoch R,Watkins S,Berry C,et al.The index of microcirculatory resistance measured acutely predicts the extent and severity of myocardial infarction in patients with ST-segment elevation myocardial infarction[J].JACC Cardiovasc Interv,2010,3(7):715-722
[8]Valgimigli M,Campo G,Malagutti P,et al.Persistent coronary no flow after wire insertion is an early and readily available mortality risk factor despite successful mechanical intervention in acute myocardial infarction: a pooled analysis from the STRATEGY(Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent Versus Abciximab and Bare-Metal Stent in Acute Myocardial Infarction)and MULTISTRATEGY(Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study)trials[J].JACC Cardiovasc Interv,2011,4(1):51-62.
[9]Kleinbongard P,Bose D,Baars T,et al.Vasoconstrictor potential of coronary aspirate from patients undergoing stenting of saphenous vein aortocoronary bypass grafts and its pharmacological attenuation[J].Circ Res,2011,108(3):344-352.
[10]Heusch G.Adenosine and maximum coronary vasodilation in humans:myth and misconceptions in the assessment of coronary reserve[J].Basic Res Cardiol,2010,105(1):1-5.
[11]Burzotta F,De VitaM,Gu YL,et al.Clinical impact of thrombectomy in acute ST-elevation myocardial infarction: an individual patient-data pooled analysis of 11 trials[J].Eur Heart J,2009,30(18):2193-2203.
[12]Kofoed KF,Kelbaek H,Thuesen L,et al.Left ventricular contractile function after distal protection in primary percutaneous coronary intervention:results from the Drug Elution and Distal Protection in STElevation Myocardial Infarction trial[J].Int J Cardiol,2011,146(3):395-398.
[13]Heusch G,Kleinbongard P,Bose D,et al.Coronary microembolization: from bedside to bench and back to bedside[J].Circulation,2009,120(18):1822-1836.
[14]Van't Hof AW,ten Berg J,Heestermans T,et al.Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, doubleblind, randomised controlled trial[J].Lancet,2008,372(9638):537-546.
备注/Memo
- 备注/Memo:
- 收稿日期：2015-04-06.
通讯作者：孙冬冬，主治医师，主要从事冠心病疾病研究 Email：51483696@qq.com
作者简介：孙雷，住院医师，硕士 Email：87163161@qq.com @qq.com
常用功能
统计/Statistics
- 摘要浏览/Viewed798
- 评论/Comments
